Hightide Therapeutics' HTD1801 Outperforms Dapagliflozin in Phase III Diabetes Trial

Reuters

2025/12/02

Hightide <a href="https://laohu8.com/S/LENZ">Therapeutics</a>' HTD1801 Outperforms Dapagliflozin in Phase III Diabetes Trial

HighTide Therapeutics Inc. has announced positive topline results from its Phase III HARMONY trial evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM). The study demonstrated that HTD1801 achieved the primary endpoint, showing greater HbA1c reduction and superior improvements in key cardiometabolic markers compared to dapagliflozin. These results, which have been announced by the company, reinforce the potential of HTD1801 to address metabolic drivers of T2DM progression while delivering cardiometabolic benefits. The company noted that HTD1801 has previously received two Fast Track designations and one Orphan Drug designation from the US FDA. It is not specified if the full results have been or will be presented at a scientific meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hightide Therapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251202-11938100), on December 02, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2588701661"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588701661\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588701661?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-02 08:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588701661","market":"fut","top_or_hot":-1,"title":"Hightide Therapeutics' HTD1801 Outperforms Dapagliflozin in Phase III Diabetes Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hightide <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' HTD1801 Outperforms Dapagliflozin in Phase III Diabetes Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HighTide Therapeutics Inc. has announced positive topline results from its Phase III HARMONY trial evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM). The study demonstrated that HTD1801 achieved the primary endpoint, showing greater HbA1c reduction and superior improvements in key cardiometabolic markers compared to dapagliflozin. These results, which have been announced by the company, reinforce the potential of HTD1801 to address metabolic drivers of T2DM progression while delivering cardiometabolic benefits. The company noted that HTD1801 has previously received two <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> designations and one Orphan Drug designation from the US FDA. It is not specified if the full results have been or will be presented at a scientific meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hightide Therapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251202-11938100), on December 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hightide Therapeutics' HTD1801 Outperforms Dapagliflozin in Phase III Diabetes Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHightide Therapeutics' HTD1801 Outperforms Dapagliflozin in Phase III Diabetes Trial\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-12-02 08:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hightide <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' HTD1801 Outperforms Dapagliflozin in Phase III Diabetes Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HighTide Therapeutics Inc. has announced positive topline results from its Phase III HARMONY trial evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM). The study demonstrated that HTD1801 achieved the primary endpoint, showing greater HbA1c reduction and superior improvements in key cardiometabolic markers compared to dapagliflozin. These results, which have been announced by the company, reinforce the potential of HTD1801 to address metabolic drivers of T2DM progression while delivering cardiometabolic benefits. The company noted that HTD1801 has previously received two <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> designations and one Orphan Drug designation from the US FDA. It is not specified if the full results have been or will be presented at a scientific meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hightide Therapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251202-11938100), on December 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDLMGZy0:1","article_id":"2588701661","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588701661","pubTimestamp":1764633646,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"HighTide Therapeutics Inc. has announced positive topline results from its Phase III HARMONY trial evaluating HTD1801 in patients with type 2 diabetes mellitus . The study demonstrated that HTD1801 achieved the primary endpoint, showing greater HbA1c reduction and superior improvements in key cardiometabolic markers compared to dapagliflozin. These results, which have been announced by the company, reinforce the potential of HTD1801 to address metabolic drivers of T2DM progression while delivering cardiometabolic benefits. The company noted that HTD1801 has previously received two Fast Track designations and one Orphan Drug designation from the US FDA. It is not specified if the full results have been or will be presented at a scientific meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02511":"君圣泰医药-B"},"translate_title":"Hightide Therapeutics的HTD1801在III期糖尿病试验中优于达格列净","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02511":0.9},"content_text":"Hightide Therapeutics' HTD1801 Outperforms Dapagliflozin in Phase III Diabetes Trial\n    \n\n        HighTide Therapeutics Inc. has announced positive topline results from its Phase III HARMONY trial evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM). The study demonstrated that HTD1801 achieved the primary endpoint, showing greater HbA1c reduction and superior improvements in key cardiometabolic markers compared to dapagliflozin. These results, which have been announced by the company, reinforce the potential of HTD1801 to address metabolic drivers of T2DM progression while delivering cardiometabolic benefits. The company noted that HTD1801 has previously received two Fast Track designations and one Orphan Drug designation from the US FDA. It is not specified if the full results have been or will be presented at a scientific meeting.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hightide Therapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251202-11938100), on December 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}